Walgreens closing stores as 25% continue to struggle

The financial woes at Walgreens continue, with the pharmacy chain announcing it will be closing a “significant” number of its remaining 8,700 stores as part of a multi-year plan to restructure its business. 

The news came during a Thursday earnings call with CEO Tim Wentworth. As to when the closures will begin, Wentworth said “changes are imminent,” noting that roughly 25% of Walgreens locations are not profitable. The shuttering of many of those stores will happen in phases over the next three years. 

Beyond this move, more stores could fall into closure if performance does not improve. However, Wentworth said that most employees will be offered jobs elsewhere and did not add any specifics regarding staff layoffs.

Walgreens has been plagued by falling sales, made worse by inflation that has caused a drop in sales at many pharmacies nationwide. The company’s stock currently sits at its lowest level in decades.

Despite its struggling stores, Walgreens still expects to report profits for fiscal year 2024, the company said. 

Competitors shutting their doors

Other retail giants have had similar issues, With Rite Aid closing more than 200 stores in April. In the same month, Walmart also announced the closure of all of its provider clinics and telehealth services, citing the lack of profitability for its Walmart Health spinoff. However, Walmart pharmacies at its retail locations will remain in operation.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.